About Brexucabtagene Autoleucel  1 × 10⁶ anti-CD19 CAR-positive viable T cells/kg (Maximum allowable dos
            
            Class: | CAR T-cell therapy  
Use: | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least one prior therapy  
Adult dose: | 1 × 10⁶ anti-CD19 CAR-positive viable T cells/kg (maximum dose of 1 × 10⁸ anti-CD19 CAR-positive viable T cells based on patient weight)  
Pediatric dose: | Safety and efficacy not established in pediatric patients  
Side effects: | Cytokine release syndrome (CRS), neurological toxicities (including encephalopathy), infections, h
         
        
            
                
                
                    
                        Drug Class
                    
                    CAR T-cell therapy
                 
                
                
                    
                        Uses & Indications
                    
                    Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least one prior therapy
                 
                
                
                    
                        Storage Requirements
                    
                    Store at -196°C in the vapor phase of liquid nitrogen; do not thaw until ready to use
                 
                
                
                    
                        Manufacturer & Packaging
                    
                    
                        Manufacturer: GILEAD SCIENCES IRELAND UC (CARRIGTOHILL-IRELAND), Ireland
                    
                    
                    Package Size
                    Bag
                    
                    
                    Price & Supplier
                    
                        Price in UAE: AED 1924694.00
                    
                    
                 
             
            
                
                
                    
                        Dosage Information
                    
                    
                        Adult Dose
                    
                    
                        1 × 10⁶ anti-CD19 CAR-positive viable T cells/kg (maximum dose of 1 × 10⁸ anti-CD19 CAR-positive viable T cells based on patient weight)
                    
                    
                        Pediatric Dose
                    
                    
                        Safety and efficacy not established in pediatric patients
                    
                 
                
                
                    
                        Side Effects
                    
                    Cytokine release syndrome (CRS), neurological toxicities (including encephalopathy), infections, hypogammaglobulinemia, and infusion-related reactions
                 
             
         
        
        
            
                Contraindications & Precautions
            
            Hypersensitivity to any component of the product; active uncontrolled infection; severe pre-existing neurological conditions
         
        
        
            
                Important Warnings
            
            Risk of CRS and neurological toxicities; monitor patients closely for signs of these conditions; ensure availability of supportive care and treatment for CRS (e.g., tocilizumab)
         
        
        
        
        
        
        
        
        
            
                Medical Disclaimer
            
            
                This information is for educational purposes only and should not replace professional medical advice. 
                Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication. 
                The information presented here is specific to medicines available in UAE pharmacies and is regularly updated 
                to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.